



March 5, 2025

Company name LinqMed Inc.  
Representative Yukie Yoshii, President and CEO

## LinqMed Wins Grand Prize at Go Global! ENGLISH Pitch Competition 2024 FINAL PITCH @ Blockbuster TOKYO

LinqMed Inc. (President and CEO: Yukie Yoshii; Headquarters: Chiba City; hereinafter the “Company”) is pleased to announce that it has won the Grand Prize at the “Go Global! ENGLISH Pitch Competition 2024 FINAL PITCH” hosted by Blockbuster TOKYO (Tokyo).

The “Go Global! ENGLISH Pitch Competition 2024 FINAL PITCH” is an English pitch competition designed to accelerate and support the overseas expansion of startups in the drug discovery and medical fields, with the aim of realizing Tokyo as the world’s leading startup city. The Company received this award in recognition of the expected global expansion of its next-generation radiopharmaceutical, the innovative “visible” cancer therapy, which utilizes the radioisotope  $^{64}\text{Cu}$  and can be used for both cancer diagnosis and treatment.



### Comment from Yukie Yoshii, President and CEO of LinqMed Inc.:

*“We are deeply honored to receive the Grand Prize at the Go Global! ENGLISH Pitch Competition 2024 FINAL PITCH. We are very pleased that our business achievements to date and our policy for overseas expansion have been recognized. We are developing cancer therapeutics and diagnostics using  $^{64}\text{Cu}$ , a radioisotope of copper, and we will continue to work diligently to expand our innovative “Visible” cancer radiotherapeutics overseas and help many patients around the world.”*



### **About Go Global! ENGLISH Pitch Competition 2024 FINAL PITCH**

Blockbuster TOKYO has held the first and second preliminary rounds of the “Go Global! ENGLISH Pitch Competition 2024,” an English pitch competition designed to accelerate and support the overseas expansion of startups in the drug discovery and medical fields. Six companies selected as finalists participated in the FINAL PITCH. <https://www.link-j.org/event/article-45665.html>

### **About LinqMed**

LinqMed Inc. is an R&D start-up company developing radiopharmaceuticals to provide innovative “visible” anti-cancer treatments to patients. Our mission is “Link for Life -Linking Innovative Science and Medicine for Your Health and Happiness”. LinqMed Inc. has been launched as a certified venture company of the National Institutes for Quantum Sciences and Technology (QST). We are developing radiopharmaceuticals using a copper radioisotope  $^{64}\text{Cu}$ , which can be used for diagnosis and therapy, simultaneously.

URL : <https://linqmed.net/>

**Inquiries:**

**LinqMed Inc.**

Email: [linqmed@linqmed.co.jp](mailto:linqmed@linqmed.co.jp)